Navigation Links
Unilens Vision Reports Record First Quarter Earnings and Royalty Income

First Quarter Net Income Increases 22% and Royalty Income Increases 29%

From Prior Year

LARGO, Fla., Nov. 29 /PRNewswire-FirstCall/ -- Unilens Vision Inc. (OTC Bulletin Board: UVICF) (TSX Venture Exchange: UVI), which develops, licenses, manufactures, distributes and markets specialty contact lenses, today reported its operating results for the first quarter of FY2008.

Net sales, excluding royalty income, for the quarter ended September 30, 2007 increased to $1,673,361 compared with $1,604,776 in the quarter ending September 30, 2006, an increase of 4.3%. The increase was primarily the result of continued growth of the Company's C-Vue multifocal contact lenses, which increased approximately 11% in the current quarter, which was partially offset by sales of our replacement products lines that declined as expected.

Net Income for the quarter increased 22% to a record first quarter of $377,296, or $0.08 per diluted share, compared with $310,492, or $0.07 per diluted share in the prior-year period.

Royalty income for the quarter increased 28.6% to a record first quarter of $612,799 compared with $476,550 in the prior-year quarter. Sales of licensed products by our licensee Bausch & Lomb continue to accelerate, resulting in the record quarterly royalty.

Income before taxes for the quarter ended September 30, 2007 increased 20% to $616,501, compared with $515,183 in the prior-year quarter. After recording income tax expense of $239,205, Unilens reported net income of $377,296, or $0.08 per diluted share. In the first quarter of FY2007, the Company reported net income of $310,492, or $0.07 per diluted share, after recording income tax expense of $204,691.

"We are pleased with our first quarter operating results and are optimistic regarding the outlook for our operating results for the remainder of the current fiscal year," stated Michael J. Pecora, Chief Executive Officer of Unilens Vision Inc., "Sales of our C-Vue disposable multifocal lenses continues to increase as well as the license royalties from Bausch and Lomb which provides a healthy stream of profitable revenues."

"I am also pleased to report that we recently paid our regular quarterly cash dividend of $0.09 per share, in accordance with a dividend policy adopted by our Board of Directors that is intended to allow our shareholders to share directly in the Company's future earnings growth," concluded Mr. Pecora. The Company's regular quarterly cash dividend was paid on November 28, 2007 to shareholders of record at the close of business on November 14, 2007.

About Unilens Vision Inc. - "The Eye Care Professionals Specialty Contact Lens Company"

Established in 1989, Unilens Vision Inc., through its wholly owned subsidiary Unilens Corp., USA, located in Largo, Florida, develops, licenses, manufactures, distributes and markets specialty contact lenses under the C-Vue, Unilens, Sof-Form, Aquaflex, SoftCon, Lombart, and LifeStyle brands. Additional information on the Company may be accessed on the Internet at The Company's common stock is listed on the OTC Bulletin Board under the symbol "UVICF" as well as the Canadian TSX Venture Exchange under the symbol "UVI".

(Note: All financial information in this release is stated in U.S. Dollars.)

The information contained in this news release, other than historical information, consists of forward-looking statements that involve risk and uncertainties that could cause actual results to differ materially from those described in such statements. For a discussion of certain factors that could cause actual results to differ materially from those described in the forward- looking statements, please refer to the Company's most recent filings with the SEC and the TSX Venture Exchange. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

For more information, please contact:

Leonard F. Barker, CFO, Unilens Vision Inc. at (727) 544-2531




(All figures in U.S. Dollars)


Three Months Ended Three Months Ended

September 30, 2007 September 30, 2006

Sales $1,673,361 $1,604,776

Cost of sales 904,397 830,630

768,964 774,146

Expenses 754,952 752,707

Income from operations 14,012 21,439

Other items:

Royalty income 612,799 476,550

Other (expense) income (27,141) 990

Remeasurement income 2,541 3,377

Interest income 14,290 12,827

602,489 493,744

Income before tax 616,501 515,183

Income tax expense 239,205 204,691

Net income for the period $377,296 $310,492

Net income per common share:

Basic $0.08 $ 0.07

Diluted $0.08 $ 0.07


Provided (used) by:

Operating activities $689,258 $330,684

Investing activities (28,123) (38,125)

Financing activities (1,744,008) (1,113,918)

Decrease in cash $(1,082,873) $(821,359)


September 30, 2007 June 30, 2007

Cash $881,380 $1,961,712

Total assets 6,611,857 7,987,808

Current liabilities 809,766 819,005

Total liabilities 809,766 819,005

Stockholders' equity $5,802,091 $7,168,803

SOURCE Unilens Vision Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Unilens Names Eschenbach Optik Exclusive Worldwide Distributor of the UniVision(R) Low Vision Lens
2. Vision restoration therapy shown to improve brain activity in brain injured patients
3. Mouse vision has a rhythm all its own
4. HEI, Inc. Announces Sale of RFID Division Assets
5. QUANTEL Intends to Strengthen its Dermatology/ Aesthetics Division With the Acquisition of WaveLight Aesthetic GmbH
6. The aye-ayes have it: The preservation of color vision in a creature of the night
7. Can brain-injured, partially-blind stroke patients regain some of their lost vision?
8. HEI, Inc. Closes on Sale of RFID Division Assets
9. Elliott Extremely Dissatisfied With Genzyme Bid for Bioenvision; Believes Offer Significantly Undervalues Company
10. Colorado Medical School Receives Provisional Accreditation
11. Poor Senior Vision Often a Window on Disease
Post Your Comments:
(Date:10/13/2015)... MA (PRWEB) , ... October 13, 2015 , ... Protein ... of the body, including muscle, bone, and blood. But how much protein does the ... complicated than it might seem, according to the October 2015 issue of Harvard ...
(Date:10/13/2015)... ... October 13, 2015 , ... T-System and Centegra ... than 59,000 emergency department visits per year, today announced the successful and rapid ... improve clinical, operational and financial outcomes. , In less than four ...
(Date:10/13/2015)... ... October 13, 2015 , ... World Patent Marketing , a vertically ... melting invention that helps people in clearing snow away from the streets and driveways. ... at 3.8% per year," says Scott Cooper, CEO and Creative Director of World Patent ...
(Date:10/13/2015)... ... October 13, 2015 , ... Thermi, ... the newest professional to introduce the latest development, ThermiVa® temperature controlled radiofrequency to ... leading professional in Obstetrics and Gynecology and a pioneer in the field of ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... and the Florida Apartment Association (FAA) has partnered with the Florida Department of ... the demand. , The FAA Smoke-Free Multifamily Housing Program launched last week ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... WuXi PharmaTech (Cayman) Inc. (NYSE:  WX), a ... serving the pharmaceutical, biotechnology, and medical device industries, ... version of OncoWuXi, the first App in the ... and data on the go.  The OncoWuXi App ... to identify relevant tumor models for use in ...
(Date:10/13/2015)... Oct. 13, 2015  The Wyss Institute ... today announced the launch of its latest ... will introduce imaging reagents providing super-resolution capabilities ... of expensive specialized instruments. The announcement follows ... Office of Technology Development (OTD) and ...
(Date:10/13/2015)... -- --> --> Opportunities ... the Asthma and COPD Therapies market? Which areas are going ... new report shows you potential revenues to 2025, assessing data, ... 260 tables, charts, and graphs. Discover the most lucrative areas ... study lets you assess forecasted sales at overall world market ...
Breaking Medicine Technology: